Non-metastatic Prostate Cancer
10
1
3
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
30%
3 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
A Study to Assess Alpha DaRT224 for the Treatment of Men With Non-metastatic Locally Recurrent Prostate Cancer
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
PROState Pathway Embedded Comparative Trial
Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer